Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-28

Clinical Trial Update: 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adjunctive infliximab for bipolar depression has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Infliximab (infliximab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Bipolar Depression | Phase 2 | Status: COMPLETED | Results posted: 2021-07-28